Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Journal of Hematology & Oncology
|
April 30, 2014
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri, et al.
Stem Cells and Development
|
May 31, 2012
Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells
Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Ejhaem
|
April 15, 2026
Reciprocal Clonal Dynamics of Independent <i>FLT3</i> D835V-Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib
Kai Osone, Seiichiro Katagiri, SungGi Chi, et al.
Leukemia Research Reports
|
May 3, 2017
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
Seiichiro Katagiri, Tetsuzo Tauchi, Keiko Ando, et al.
Ejhaem
|
July 18, 2022
Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment
Mitsuru Moriyama, Yasuo Aota, Masahiro Okabe, et al.
International Journal of Hematology
|
February 17, 2016
Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation
Seiichiro Katagiri, Moritaka Gotoh, Kazuya Tone, et al.
Therapeutic Advances in Hematology
|
April 17, 2024
Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy
Satoshi Uchiyama, Kentaro Fukushima, Seiichiro Katagiri, et al.
Drug Design, Development and Therapy
|
September 5, 2014
Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
Junko H Ohyashiki, Kazushige Ohtsuki, Izuru Mizoguchi, et al.
Oncotarget
|
October 21, 2017
Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
Satoshi Imanishi, Ryoko Takahashi, Seiichiro Katagiri, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
November 20, 2024
Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system
Katsuhiro Ohyama, Seiichiro Katagiri, Satoshi Takahashi, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Journal of Hematology & Oncology
|
April 30, 2014
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
Seiichi Okabe, Tetsuzo Tauchi, Seiichiro Katagiri, et al.
Stem Cells and Development
|
May 31, 2012
Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells
Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, et al.
Ejhaem
|
April 15, 2026
Reciprocal Clonal Dynamics of Independent <i>FLT3</i> D835V-Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib
Kai Osone, Seiichiro Katagiri, SungGi Chi, et al.
Leukemia Research Reports
|
May 3, 2017
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia
Seiichiro Katagiri, Tetsuzo Tauchi, Keiko Ando, et al.
Ejhaem
|
July 18, 2022
Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment
Mitsuru Moriyama, Yasuo Aota, Masahiro Okabe, et al.
International Journal of Hematology
|
February 17, 2016
Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation
Seiichiro Katagiri, Moritaka Gotoh, Kazuya Tone, et al.
Therapeutic Advances in Hematology
|
April 17, 2024
Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy
Satoshi Uchiyama, Kentaro Fukushima, Seiichiro Katagiri, et al.
Drug Design, Development and Therapy
|
September 5, 2014
Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
Junko H Ohyashiki, Kazushige Ohtsuki, Izuru Mizoguchi, et al.
Oncotarget
|
October 21, 2017
Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
Satoshi Imanishi, Ryoko Takahashi, Seiichiro Katagiri, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
November 20, 2024
Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system
Katsuhiro Ohyama, Seiichiro Katagiri, Satoshi Takahashi, et al.
Page
of 5